Posted by Michael Wonder on 16 Aug 2024
EMA confirms acceptance of marketing application for AVT06, a proposed biosimilar to Eylea (aflibercept)
15 August 2024 - The approvals process is anticipated to be completed in the third quarter of 2025.
Alvotech and Advanz Pharma today announced that the EMA has accepted a marketing authorisation application for AVT06, Alvotech’s proposed biosimilar to Eylea (aflibercept).
